ArticleScientific reports2026
Rational design, synthesis, and antimicrobial evaluation of novel 1,2,3-triazole hybrids: structure-activity relationships, molecular docking, and DFT studies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of novel 2,4-dichlorophenyl-1,2,3-triazole derivatives and their structural hybrids incorporating chalcone, hydrazone, thio/semicarbazide, carbamate, and pyrazole moieties were rationally designed, synthesized, and characterized. The antimicrobial activity of the synthesized compounds was evaluated against Gram-positive and Gram-negative bacteria, as well as Candida albicans, revealing clear structure-dependent activity profiles. Among the tested compounds, the parent triazole-acetyl scaffold (compound 3) exhibited the most consistent broad-spectrum activity, with MIC values of 22.5 mg/mL against E. coli, H. pylori, and C. albicans, and 11.25 mg/mL against B. cereus and S. aureus. Structure-activity relationship (SAR) and ADME analyses indicated that a balance between lipophilicity and polarity plays a critical role in modulating antimicrobial performance and membrane permeability. Molecular docking studies against Staphylococcus aureus topoisomerase IV (PDB: 4URN) revealed favorable binding interactions of the active compounds within the enzyme active site. Complementary density functional theory (DFT) calculations provided insights into electronic properties and reactivity trends, supporting the observed biological behavior. Overall, the results suggest that the 2,4-dichlorophenyl-1,2,3-triazole scaffold represents a promising starting point for further optimization, with antimicrobial activity governed by a balance between electronic properties and physicochemical factors influencing membrane permeability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.